Capricor Therapeutics announced the scale-up to expand manufacturing capacity of CAP-1002 to its new state-of-the-art manufacturing facility, intended for commercial use, subject to regulatory approval, located in San Diego. Furthermore, the Company announced that Cohort B of its HOPE-3, Phase 3 clinical study is enrolling rapidly and is expected to complete full enrollment (n=44) in the second quarter of 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.555 USD | +1.55% | +3.56% | +12.88% |
Apr. 29 | Transcript : Capricor Therapeutics, Inc. - Special Call | |
Apr. 24 | Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.88% | 172M | |
+8.84% | 105B | |
-1.16% | 104B | |
+5.79% | 22.94B | |
-12.44% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.18% | 16.96B | |
+7.86% | 14.16B | |
+38.20% | 12.63B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization